Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating KD6001 in combination with an anti-PD-1 antibody for advanced melanoma is underway, with no status rep…
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) [Phase 1, Phase 2]
Phase 1/2 study evaluating Epacadostat in combination with Nivolumab in select advanced cancers; results have been posted following completi…
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma [Phase 2]
A Phase 2 clinical trial update evaluating the combination of toripalimab and temozolomide as neoadjuvant therapy for resectable stage III m…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence [Phase 3]
Phase 3 trial evaluating adjuvant bempegaldesleukin plus nivolumab versus nivolumab alone after complete resection of melanoma at high risk …
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 [Phase 4]
Phase 4 clinical trial update evaluating heart function during PD-1–inhibiting immunotherapy in melanoma and non-small cell cancer patients.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma [Phase 2]
Phase 2 trial evaluating adjuvant ipilimumab and nivolumab in high-risk ocular melanoma.
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Study of Temzolomide and Gleevec in Advanced Melanoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating temzolomide and Gleevec in advanced melanoma has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma [Phase 3]
Phase 3 trial update for Prolgolimab 250 mg every 3 weeks in unresectable or metastatic melanoma.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Clinical trial update for CB-839 in combination with nivolumab in melanoma, clear cell renal cell carcinoma, and non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NKTR-214 in combination with nivolumab and other anti-cancer therapies in select advanced solid tumors completed …
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]
Phase 1/2 trial REVEAL exploring NKTR-262 with NKTR-214 and nivolumab in various locally advanced/metastatic solid tumors was terminated; re…
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Immunological Variables Associated to ICI Toxicity in Cancer Patients [Phase 2]
A Phase 2 clinical trial investigating immunological variables associated with immune checkpoint inhibitor toxicity in cancer patients.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Radiation and Combination Immunotherapy for Melanoma [Phase 2]
Phase 2 trial evaluating the combination of radiation therapy and immunotherapy for metastatic melanoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-02Clinical Trial Update: Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with all-trans retinoic acid in advanced melanoma has completed, with res…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) [Phase 2]
Phase 2 trial assessing pembrolizumab (MK-3475) in metastatic melanoma patients naive to immune therapy, using systems biology for tumor mic…
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 study comparing BCD-217 followed by BCD-100 versus BCD-100 monotherapy as first-line treatment in unresectable or metastatic melanom…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of Aldesleukin and Pembrolizumab in patients with metastatic or advanced melanoma has be…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma [NA]
A completed clinical trial studied an interactive tailored website designed to promote sun protection and skin self-check behaviors in melan…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Phase 2]
Phase 2 trial investigating tumor infiltrating lymphocytes (TIL) immunotherapy for metastatic melanoma has completed; results posted in 2023…
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer [Phase 3]
Phase 3 trial evaluating SPY-X for sentinel node localization in melanoma and breast cancer has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas [Phase 1, Phase 2]
Phase 1/2 trial evaluating nivolumab with or without ipilimumab in younger patients with recurrent or refractory solid tumors or sarcomas; c…
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery [Phase 3]
Phase 3 trial update on using fluorescence for sentinel lymph node identification in cancer surgery; completed study.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. [Phase 2]
Phase II trial evaluating stereotactic body radiotherapy with concurrent anti-PD1 therapy in metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma [Phase 3]
Final results from a Phase 3 trial comparing NKTR-214 (bempegaldesleukin) plus nivolumab versus nivolumab alone in previously untreated inop…